• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Infect Dis. Seroprevalence of Crimean-Congo Hemorrhagic Fever Virus, Bulgaria

Giuseppe

Emeritus
[Source: Emerging Infectious Diseases Journal, full page: (LINK). Extract, edited.]

Letter

Seroprevalence of Crimean-Congo Hemorrhagic Fever Virus, Bulgaria



To the Editor:

Crimean-Congo hemorrhagic fever (CCHF) is endemic in southern Russia, southeastern Europe, Africa, the Middle East, and southwestern Asia (1). The incidence and spread of the disease have increased in recent years. In Bulgaria, located on the Balkan Peninsula, CCHF is endemic. The disease was first described in the country in 1952 (3). Since then, a mandatory reporting system has been introduced. Most of Bulgaria is an ecologically favorable environment for CCHF virus (CCHFV) circulation in nature. In the 1970s, numerous virologic and serologic studies were performed by Vasilenko et al., who showed that the most affected age group was 21?50 years and that most of those with CCHF were male (65%) (cited in [2]). A genetic study showed that CCHFV strains in Bulgaria cluster together with strains from other Balkan countries and Russia (3). A vaccine consisting of chloroform-inactivated CCHFV was developed in 1974, and the currently used vaccine strain, isolated from a Bulgarian patient, was characterized genetically (4).


(?)
-
------
 
Back
Top